Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that finasteride treatment was more effective in treating prostatitis-related hemospermia compared to non-prostatitis cases, particularly after excluding sonographically abnormal cases.

This review discusses the role of the TOR pathway in aging and suggests that rapamycin could potentially target age-related diseases, but reports no new clinical results.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review discusses the properties and therapeutic potentials of beta-sitosterol, highlighting a need for more detailed studies on its mechanisms and long-term effects in humans; it reports no new results.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This study found that PRO 160/120 and Finasteride showed similar effectiveness in improving urinary symptoms and quality of life in patients with benign prostatic hyperplasia over 48 weeks.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In castrated rats, this study found that triterpenoids from Ganoderma lucidum inhibited both types of 5α-reductase and reduced prostate growth linked to testosterone but not dihydrotestosterone.

Both drugs lower DHT levels, with GI198745 being more effective.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

This review discusses the nutrient profile and potential health benefits of pumpkin and watermelon seeds, concluding they are underutilized and could be developed into various nutraceuticals.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This case report suggests that oral finasteride, used for benign prostatic hyperplasia, may be associated with intraoperative floppy-iris syndrome during cataract surgery.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.